$240,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R. 4366, Consolidated Appropriations Act of 2024, including provisions relating to health care H.R. 5027/S. 4469, Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 7085, BIOSECURE Act S. 3558, to prohibit contracting with certain biotechnology providers, and for other purposes Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance FY 2025 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care
HR 5074/S. 4510, Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments (PATIENT) Act of 2023 Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Proposed CY 2025 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC)"
You can find more data on corporate lobbying on Quiver Quantitative.
AKBA Hedge Fund Activity
We have seen 54 institutional investors add shares of AKBA stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ACADIAN ASSET MANAGEMENT LLC removed 4,063,383 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,363,665
- BLACKROCK, INC. added 3,558,723 shares (+30.6%) to their portfolio in Q3 2024, for an estimated $4,697,514
- NORTHERN TRUST CORP added 1,198,213 shares (+274.3%) to their portfolio in Q3 2024, for an estimated $1,581,641
- VANGUARD GROUP INC added 794,035 shares (+8.6%) to their portfolio in Q3 2024, for an estimated $1,048,126
- STATE STREET CORP added 683,287 shares (+24.9%) to their portfolio in Q3 2024, for an estimated $901,938
- QUBE RESEARCH & TECHNOLOGIES LTD removed 420,887 shares (-24.1%) from their portfolio in Q3 2024, for an estimated $555,570
- WELLINGTON MANAGEMENT GROUP LLP added 404,718 shares (+inf%) to their portfolio in Q3 2024, for an estimated $534,227
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
